comparemela.com
Home
Live Updates
Innate Pharma SA: SAR579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies : comparemela.com
Innate Pharma SA: SAR'579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
SAR'579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner
Related Keywords
France ,
Zeiten ,
Mecklenburg Vorpommern ,
Germany ,
French ,
Henry Wheeler ,
Stefan Klotter ,
Mondher Mahjoubi ,
Arthur Rouill ,
Twitter ,
Astrazeneca ,
Linkedin ,
Nasdaq ,
French Financial Markets Authority ,
Exchange Commission ,
Euronext ,
Company Annual Report On Form ,
Drug Administration ,
Innate Pharma ,
Euronext Paris ,
Fast Track Designation ,
Track Designation ,
Chief Executive Officer ,
Engager Therapeutics ,
Private Securities Litigation Reform Act ,
Risk Factors ,
Universal Registration Document ,
Annual Report ,
Stabile Ertr ,
Chart Profi Stefan Klotter ,
Blue Chips ,
Yinnate ,
Dharma ,
Ph6101 ,
Eceives ,
Mast ,
Track ,
Resignation ,
Treatment ,
Haematological ,
Malignancies ,
comparemela.com © 2020. All Rights Reserved.